Skip to content

DNA Repair in Patients With Stable Angina.

DNA Repair in Patients With Stable Angina.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04453267
Acronym
DECODE II
Enrollment
172
Registered
2020-07-01
Start date
2020-02-05
Completion date
2024-08-01
Last updated
2022-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Arteriosclerosis, Coronary Artery Disease, DNA Damage, DNA Repair Abnormality

Brief summary

Markers of DNA damage and repair are present in both atherosclerotic plaques and peripheral blood mononuclear cells of patients with coronary artery disease. A positive correlation has been observed between the level of DNA damage and the severity of atherosclerotic lesions, as well as atherogenic risk factors such as smoking, hypertension and hyperlipidaemia. A number of in-vitro studies have implicated defective DNA repair in the development and progression of atherosclerotic lesions. In mouse models of atherosclerosis, the DNA repair signalling cascade has been shown to be amenable to pharmacological intervention and overexpression of specific repair proteins attenuate the development of atherosclerotic plaques. However, data regarding the role of DNA repair in the pathogenesis of atherosclerosis in humans are lacking. We have preliminary data indicating reduced DNA repair activity in patients with stable angina. This study will determine the molecular basis and the biological consequences of this observation.

Interventions

None listed

Sponsors

University Hospital Southampton NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Age ≥18 years * Ability to provide written informed consent

Exclusion criteria

* Age ≥ 80 years * Inability to provide written informed consent * Presentation with an acute coronary syndrome * Severe valvular heart disease * Hypertrophic cardiomyopathy * Left ventricular ejection fraction ≤ 35% * Prior coronary revascularisation (surgical or percutaneous) * Diabetes Mellitus * Clinical evidence of peripheral vascular disease * Prior history of cerebrovascular disease * Malignancy * Active inflammatory disorders (e.g. rheumatoid arthritis/connective tissue disorder) * Renal impairment eGFR \<60ml/min/1.73m2 * Anaemia (Hb \<100g/dL)

Design outcomes

Primary

MeasureTime frameDescription
Association between monocytes exhibiting reduced base excision repair and/or double strand break repair activity in patients with stable angina as compared to patients without coronary artery disease.Blood will be collected at the time of hospital admission for index procedure. No follow-up of patients will be required.This will be assessed using real-time polymerase chain reaction, western blotting and proteosomal degradation assay.
Reduced DNA repair activity is associated with impaired response to oxidative stress in human monocytes in patients with stable angina in comparison to an age and gender matched control.Blood will be collected at the time of hospital admission for index procedure. No follow-up of patients will be required.

Countries

United Kingdom

Contacts

Primary ContactThomas R Gilpin, MBBCh
thomas.gilpin@uhs.nhs.uk0044 (0)2380777222
Backup ContactZoe Nicholas, BSc
zoe.nicholas@uhs.nhs.uk0044 (0)2380777222

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026